



## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

#### **Company Statement on Site 1 – API facility, Bengaluru**

“The U.S. Food and Drug Administration (US FDA) conducted a surveillance inspection of our API facility (Site 1), located at Bengaluru, Karnataka, between the 16th to 20th September 2024

Three observations were cited at the end of the Inspection, which the Company will be addressing within the stipulated time. The Company does not foresee any impact on the business.”